BioNxt Solutions Inc. (CVE:BNXT)

BRIEF

published on 07/26/2025 at 00:05, 6 months 10 days ago

BioNxt Solutions Closes First Tranche of Debenture Placement

Private Placement Warrants Convertible Debentures Product Development BioNxt Solutions
PRESS RELEASE

published on 07/26/2025 at 00:00, 6 months 10 days ago

BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement
BioNxt Solutions Inc. closes first tranche of non-brokered private placement, raising $1,009,200 for drug delivery tech and IP development. Securities subject to statutory hold until Nov 26, 2025

Private Placement Convertible Debentures BioNxt Solutions Inc. Intellectual Property Drug Delivery Technologies
BRIEF

published on 07/23/2025 at 09:10, 6 months 13 days ago

BioNxt Advances Cladribine Thin-Film Development

Multiple Sclerosis Cladribine Drug Delivery BioNxt Solutions Sublingual Thin-Film
PRESS RELEASE

published on 07/23/2025 at 09:05, 6 months 13 days ago

BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation
BioNxt Solutions Inc. announces successful development of sublingual thin-film prototype for cladribine-based drug delivery in multiple sclerosis treatment, strengthening clinical development path

BioNxt Solutions Inc. Cladribine Drug Delivery Multiple Sclerosis Treatment Thin-film Prototype
BRIEF

published on 07/12/2025 at 00:05, 6 months 24 days ago

BioNxt Solutions Proposes Convertible Debenture Unit Offering

Private Placement Convertible Debenture Investor Information Product Development BioNxt Solutions
PRESS RELEASE

published on 07/12/2025 at 00:00, 6 months 24 days ago

BioNxt Solutions Announces Convertible Debenture Unit Private Placement
BioNxt Solutions Inc. announces $1.2M non-brokered private placement of convertible debenture units for product development and commercialization

Private Placement Convertible Debentures BioNxt Solutions Inc. Commercialization Product Development
BRIEF

published on 07/09/2025 at 03:32, 6 months 27 days ago

BioNxt Solutions Innovates Targeted Chemotherapy Drug Delivery

Precision Oncology Drug Delivery BioNxt Solutions Pharmaceutical Innovations Targeted Chemotherapy
PRESS RELEASE

published on 07/09/2025 at 03:27, 6 months 27 days ago

BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology
BioNxt Solutions Inc. announces breakthrough targeted chemotherapy delivery platform for precision oncology, focusing on tumor-specific drug release and neutralization mechanism

Precision Oncology BioNxt Solutions Inc. Drug Delivery Targeted Chemotherapy Chemotherapy Market
BRIEF

published on 07/07/2025 at 09:10, 6 months 29 days ago

BioNxt Advances Sublingual Cladribine Program for MS

Pharmaceutical Development Multiple Sclerosis Treatment BioNxt Solutions Sublingual Cladribine Patient Compliance
PRESS RELEASE

published on 07/07/2025 at 09:05, 6 months 29 days ago

BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
BioNxt Solutions receives cladribine API for BNT23001 sublingual thin-film formulation treating multiple sclerosis. Initiates clinical batch production with European partner Gen-Plus GmbH & Co KG

Multiple Sclerosis BioNxt Solutions BNT23001 Cladribine API Sublingual Film

Published on 02/05/2026 at 21:00, 33 minutes ago

Kidoz Welcomes CloudX Innovation Driving Fairer Mobile Advertising Auctions
Published on 02/05/2026 at 18:50, 2 hours 43 minutes ago

Athena Gold Provides Exploration Update From Nevada and Ontario
Published on 02/05/2026 at 17:35, 3 hours 58 minutes ago

Pentagon I Capital Corp. Enters into Letter Agreement to Complete Qualifying Transaction with Prospectiva Resources Ltd.
Published on 02/05/2026 at 16:40, 4 hours 53 minutes ago

Relevant Gold Appoints Larry Taddei to Board of Directors and Mal Karwowska as Strategic Advisor
Published on 02/05/2026 at 15:45, 5 hours 48 minutes ago

American Critical Minerals Recaps a Highly Successful 6 Months and Files Amended and Restated Technical Report

View all ACCESSWIRE

Published on 02/05/2026 at 19:27, 2 hours 6 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 2 hours 47 minutes ago

EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 3 hours 24 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 17:55, 3 hours 38 minutes ago

Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:05, 4 hours 28 minutes ago

European Research and Innovation: the Politecnico di Milano Launches an Office in Brussels

View all EQS

Published on 02/05/2026 at 19:24, 2 hours 9 minutes ago

Minutes of the Combined General Meeting
Published on 02/05/2026 at 18:24, 3 hours 9 minutes ago

LNA SANTE : 2025 annual sales
Published on 02/05/2026 at 18:06, 3 hours 26 minutes ago

Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
Published on 02/05/2026 at 18:00, 3 hours 33 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of January 30, 2026
Published on 02/05/2026 at 18:00, 3 hours 33 minutes ago

ACM - Press release 2025 results

View all LES ECHOS COMFI WIRE

News